±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 2295  |  »Ø¸´: 12
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

yalefield

½ð³æ (ÎÄ̳¾«Ó¢)

ÀϺºÒ»Ã¶

[½»Á÷] ÏÈÉùÒ©ÒµµÄ¶÷¶È£¨ENDOSTAR£©[ת]

×÷ÕߣºJingyi

¡¡¡¡2007Äê³õ£¬ÖйúµÄÒ»¼ÒÖÆÒ©¹«Ë¾ÏÈÉùÖÆÒ©ÔÚŦԼÉÏÊС£ÆäÖ÷Òª²úÆ·ÊÇ¡°¶÷¶È¡±(ENDOSTAR)£¬Ò»ÖÖÒÖÖÆÑª¹ÜÉú³¤µÄÒ©ÎÖ÷ÒªÕë¶Ô·ÇСϸ°û·Î°©(NSCLC)¡£ÕâÊÇÒ»Öַdz£ÆÕ±éµÄ¶ñÐÔÖ×Áö£¬¾­³£ÓÉÎüÑÌÓÕ·¢¡£

¡¡¡¡¼ÇµÃÒÔǰ¿´¹ýһЩÎÄÕ£¬½éÉÜͨ¹ýÒÖÖÆÑª¹ÜÉú³¤¡°¶öËÀ¡±°©Ï¸°û¡£Ã»Ïëµ½ÏÖÔÚÒѾ­³ö²úÆ·£¬¶øÇÒÊÇÕë¶ÔÖйú·Ç³£ÆÕ±éµÄ·Î°©¡£¿Éϲ¿ÉºØ¡£

¡¡¡¡µ«ÊÇ×ÐϸÑо¿Ò»Ï£¬È´·¢ÏÖÎÊÌâ¡£

    ¶÷¶ÈµÄÖ÷Òª³É·Ö(Endostatin)ÔÚ¹úÍâµÄ¶þÆÚÁÙ´²Öб»Åж¨Ã»ÓÐÃ÷ÏÔЧ¹û¡£(Note 1) µ±³õÑо¿¸ÃÒ©µÄÒ»¼ÒÃÀ¹úÉú»¯¹«Ë¾EntreMed¼¸ºõÆÆ²ú¡£²Æ¸»ÔÓÖ¾ÆÀÂÛ˵£¬¸ÃÒ©¡°Ï·¾çÐÔµÄʧ°ÜÁË¡±¡£(Note 2)
    µ«ÊÇ£¬¸Ã¹«Ë¾ÔÚÖйú×öµÄ493ÀýÈ´·¢ÏÖʹÓö÷¶È¿ÉÒÔʹ1ÄêÉú´æÂÊ´Ó31%Ôö¼Óµ½63%£¬Æ½¾ùÉú´æÊÙÃüÊǶÔÕÕ×éµÄ5±¶¡£(Note 3£©¡£

¡¡¡¡ÏÖÔÚ¶÷¶ÈÒѾ­ÔÚÖйú500¶à¼ÒҽԺʹÓã¬ÓÃÓÚÖÎÁÆÖйú´óÁ¿ÒòÎüÑ̶øµÃ·Î°©µÄ²¡ÈË¡£ºÜÆæ¹ÖΪʲô¹úÄÚÍâµÄÁÙ´²½á¹û²îÒìÕâô´ó¡£ÓÐûÓÐÄÄλרҵÈËÊ¿Ñо¿Ò»Ï¡£

Note:
1. Kulke M H et al (2006). "Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors". J. Clin. Oncol. 24: 3555-3561.
2. http://yalemedicine.yale.edu/ym_sp06/booksideas.html
3. Company Prospectus - Strong Growth Potential of Our Innovative Pharmaceutical Endu
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xjxlovelxl

ÈÙÓþ°æÖ÷ (ÖªÃû×÷¼Ò)

CA-FANS

²»Êǻѱ¨°É¡£¡£¡£¡£¡£¡£
¡¾¹«¸æ£ºÓн±ÎÊ´ð°æ½ûÖ¹¹àË®¡¿
8Â¥2008-01-17 17:17:58
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 13 ¸ö»Ø´ð

wangw2008

½ð³æ (Ö°Òµ×÷¼Ò)

´¿½àÔÚ¼ËÔº,¶éÂäÔÚ½ÌÓý²¿.

±¾ÈËÒ²Ò»Ö±ÔÚ»³ÒÉÕâ¸öÊý¾Ý£¬ÏÈÉùµÄËÄÆÚÁÙ´²Êý¾Ý×öµÄºÜ²î£¬ÖÁÓÚ£±£¬£²ÆÚµÄÊý¾ÝÔõôÀ´µÄ£®´ó¸ÅÖ»ÓÐÖйúµÄÕâ¸ö»·¾³Ï²Żá³öÏÖ£®
ÑÏÕýÉùÃ÷: ±¾ÌûÄÚÈÝÎ´Éæ¼°¹¥»÷ÈκγæÓÑ(°üÀ¨ÒÔָɣÂî»±£¬º¬É³ÉäÓ°µÈÐÎʽ),²»Ó°ÏìºÈѪ(ɽ¶«»°ºÍг)
2Â¥2007-12-19 07:07:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

¶¹¸ç

Ö÷¹ÜÇø³¤ (Ö°Òµ×÷¼Ò)

ÖÆÁ£ÄÜÊÖ

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

ÕâÑùµÄ»°Ò©ÎïûÓÐÁÆÐ§ÔõôÄÜÒ»Ö±ÔÚÁÙ´²ÉÏÓÃÄØ£¿
±ßѧ±ßÎÊ£¬²ÅÓÐѧÎÊ¡£
3Â¥2007-12-19 14:00:23
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
4Â¥2007-12-19 14:13:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 312Çóµ÷¼Á +3 Say Never 2026-04-04 3/150 2026-04-05 11:19 by guoweigw
[¿¼ÑÐ] Ò»Ö¾Ô¸ ÄϾ©º½¿Õº½Ìì´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶ +8 @taotao 2026-03-30 8/400 2026-04-05 11:15 by ·çÓêÎÞÇç
[¿¼ÑÐ] 085600µ÷¼Á +8 ¶«ÕÕÕÕÕÕ 2026-04-04 8/400 2026-04-04 22:26 by oooqiao
[¿¼ÑÐ] 413Çóµ÷¼Á +4 ¿Âijij 2026-03-31 4/200 2026-04-04 22:18 by ѧԱ6BFVa3
[¿¼ÑÐ] 338Çóµ÷¼Á +7 êɹ¦? 2026-04-03 7/350 2026-04-04 20:37 by À¶ÔÆË¼Óê
[¿¼ÑÐ] ±¾¿Æ211£¬×¨Òµ085404£¬293·ÖÇëÇóµ÷¼Á +5 Á«²Ë¾ÍÊÇź°É 2026-04-04 5/250 2026-04-04 14:08 by ÕâÊÇÒ»¸öÎÞÁĵÄê
[¿¼ÑÐ] 400·ÖÇóµ÷¼Á +3 ÞÏÞÎÇÒÄÓÍ· 2026-04-04 3/150 2026-04-04 08:41 by jp9609
[¿¼ÑÐ] Çóµ÷¼Á +4 ѹÁ¦??´ó 2026-04-03 4/200 2026-04-03 21:36 by à£à£à£0119
[¿¼ÑÐ] 295Çóµ÷¼Á +6 FZAC123 2026-04-03 6/300 2026-04-03 21:01 by zhq0425
[¿¼ÑÐ] 286Çóµ÷¼Á +8 lim0922 2026-04-02 8/400 2026-04-03 20:19 by rzh123456
[¿¼ÑÐ] ²ÄÁÏר˶µ÷¼Á +18 Ò¬Ò¬¡£ 2026-03-29 18/900 2026-04-03 16:45 by ÁáÁá0606
[¿¼ÑÐ] Ò»Ö¾Ô¸Öйú¿ÆÑ§Ôº´óѧ265Çóµ÷¼Á +9 Ìñµ­ye 2026-03-31 10/500 2026-04-03 11:10 by txp1986
[¿¼ÑÐ] ±§Ç¸ +5 ÌïºéÓÐ 2026-03-30 5/250 2026-04-03 10:24 by linyelide
[¿¼ÑÐ] ²ÄÁÏ¿¼Ñе÷¼Á +10 Gs´óÍõ 2026-04-02 10/500 2026-04-03 09:47 by ÒÅÍüÏûʧµÄž™
[¿¼ÑÐ] Çóµ÷¼Á£¡ÉúÎïÓëҽҩר˶ +4 Äæ×ªÂ½ÏÈÉú 2026-04-01 5/250 2026-04-03 08:33 by Jaylen.
[¿¼ÑÐ] 272Çóµ÷¼Á£¬½ÓÊÜ¿çרҵµ÷¼Á£¡ +4 ÏÐÓ㬠2026-03-31 4/200 2026-04-02 11:18 by guyan1000
[¿¼ÑÐ] ¸´ÊÔµ÷¼Á +7 Ë«ÂíβƦÀϰå2 2026-03-31 7/350 2026-03-31 19:49 by Dyhoer
[»ù½ðÉêÇë] ÃæÉÏ5BÄÜÉÏ»áÂ𣿠+8 redcom 2026-03-29 8/400 2026-03-31 15:53 by niuailing
[¿¼ÑÐ] 085601Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ³õÊÔ346 +4 085601³õÊÔ346 2026-03-30 4/200 2026-03-31 07:47 by jp9609
[¿¼ÑÐ] 279Çóµ÷¼Á +12 jµÄÁ¢·½ 2026-03-29 12/600 2026-03-30 20:30 by dick_runner
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û